A Phase I, Open-label, Randomized, Single-dose Study of Acalabrutinib in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (Rabeprazole) on Acalabrutinib Capsule When Administered Orally With COCA-COLA
Latest Information Update: 14 May 2021
At a glance
- Drugs Acalabrutinib (Primary) ; Rabeprazole
- Indications B-cell lymphoma; B-cell prolymphocytic leukaemia; Bladder cancer; Chronic lymphocytic leukaemia; COVID 2019 infections; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Head and neck cancer; Infections; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 29 Oct 2020 Status changed from recruiting to completed.
- 04 Aug 2020 New trial record
- 03 Aug 2020 Planned primary completion date changed from 20 Aug 2020 to 28 Aug 2020.